vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $194.8M, roughly 1.5× TOMPKINS FINANCIAL CORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 49.4%, a 46.9% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 9.4%). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
ACAD vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $194.8M |
| Net Profit | $273.6M | $96.2M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 71.7% |
| Net Margin | 96.3% | 49.4% |
| Revenue YoY | 9.4% | 152.7% |
| Net Profit YoY | 90.3% | 388.9% |
| EPS (diluted) | $1.61 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $194.8M | ||
| Q3 25 | $278.6M | $87.4M | ||
| Q2 25 | $264.6M | $82.6M | ||
| Q1 25 | $244.3M | $81.7M | ||
| Q4 24 | $259.6M | $77.1M | ||
| Q3 24 | $250.4M | $76.6M | ||
| Q2 24 | $242.0M | $72.7M | ||
| Q1 24 | $205.8M | $72.8M |
| Q4 25 | $273.6M | $96.2M | ||
| Q3 25 | $71.8M | $23.7M | ||
| Q2 25 | $26.7M | $21.5M | ||
| Q1 25 | $19.0M | $19.7M | ||
| Q4 24 | $143.7M | $19.7M | ||
| Q3 24 | $32.8M | $18.6M | ||
| Q2 24 | $33.4M | $15.7M | ||
| Q1 24 | $16.6M | $16.9M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 71.7% | ||
| Q3 25 | 12.8% | 35.6% | ||
| Q2 25 | 12.2% | 34.2% | ||
| Q1 25 | 7.9% | 31.6% | ||
| Q4 24 | 59.1% | 33.4% | ||
| Q3 24 | 12.6% | 32.0% | ||
| Q2 24 | 12.6% | 28.3% | ||
| Q1 24 | 7.4% | 30.4% |
| Q4 25 | 96.3% | 49.4% | ||
| Q3 25 | 25.8% | 27.1% | ||
| Q2 25 | 10.1% | 26.0% | ||
| Q1 25 | 7.8% | 24.1% | ||
| Q4 24 | 55.4% | 25.5% | ||
| Q3 24 | 13.1% | 24.3% | ||
| Q2 24 | 13.8% | 21.6% | ||
| Q1 24 | 8.0% | 23.2% |
| Q4 25 | $1.61 | $6.72 | ||
| Q3 25 | $0.42 | $1.65 | ||
| Q2 25 | $0.16 | $1.50 | ||
| Q1 25 | $0.11 | $1.37 | ||
| Q4 24 | $0.86 | $1.39 | ||
| Q3 24 | $0.20 | $1.30 | ||
| Q2 24 | $0.20 | $1.10 | ||
| Q1 24 | $0.10 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $938.4M |
| Total Assets | $1.6B | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $132.8M | ||
| Q3 25 | $258.0M | $193.5M | ||
| Q2 25 | $253.6M | $212.6M | ||
| Q1 25 | $217.7M | $193.1M | ||
| Q4 24 | $319.6M | $134.4M | ||
| Q3 24 | $155.1M | $132.3M | ||
| Q2 24 | $177.1M | $70.9M | ||
| Q1 24 | $204.7M | $57.1M |
| Q4 25 | $1.2B | $938.4M | ||
| Q3 25 | $917.3M | $788.8M | ||
| Q2 25 | $822.4M | $761.8M | ||
| Q1 25 | $765.2M | $741.4M | ||
| Q4 24 | $732.8M | $713.4M | ||
| Q3 24 | $577.2M | $719.9M | ||
| Q2 24 | $516.7M | $674.6M | ||
| Q1 24 | $464.0M | $667.9M |
| Q4 25 | $1.6B | $8.7B | ||
| Q3 25 | $1.3B | $8.5B | ||
| Q2 25 | $1.2B | $8.4B | ||
| Q1 25 | $1.1B | $8.2B | ||
| Q4 24 | $1.2B | $8.1B | ||
| Q3 24 | $976.9M | $8.0B | ||
| Q2 24 | $914.1M | $7.9B | ||
| Q1 24 | $855.1M | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $38.9M |
| Free Cash FlowOCF − Capex | — | $31.9M |
| FCF MarginFCF / Revenue | — | 16.4% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $38.9M | ||
| Q3 25 | $74.3M | $34.9M | ||
| Q2 25 | $64.0M | $18.9M | ||
| Q1 25 | $20.3M | $22.2M | ||
| Q4 24 | $40.4M | $95.0M | ||
| Q3 24 | $63.2M | $21.2M | ||
| Q2 24 | $25.0M | $27.3M | ||
| Q1 24 | $29.1M | $23.2M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | $73.9M | $33.9M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | — | $88.8M | ||
| Q3 24 | $63.2M | $18.9M | ||
| Q2 24 | — | $26.3M | ||
| Q1 24 | — | $21.9M |
| Q4 25 | — | 16.4% | ||
| Q3 25 | 26.5% | 38.8% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | — | 115.1% | ||
| Q3 24 | 25.2% | 24.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 30.0% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | 0.0% | 2.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 1.9% |
| Q4 25 | -0.18× | 0.40× | ||
| Q3 25 | 1.03× | 1.47× | ||
| Q2 25 | 2.40× | 0.88× | ||
| Q1 25 | 1.07× | 1.13× | ||
| Q4 24 | 0.28× | 4.82× | ||
| Q3 24 | 1.93× | 1.14× | ||
| Q2 24 | 0.75× | 1.74× | ||
| Q1 24 | 1.76× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
TMP
Segment breakdown not available.
